Does Allergen Immunotherapy Interact with Ustekinumab Aekn?
CDI records a moderate classification for Allergen Immunotherapy and Ustekinumab Aekn. The stored summary is: Ustekinumab may decrease the protective effect of allergen immunotherapy and increase risk of allergic reaction. Caution should be exercised, particularly regarding anaphylaxis risk. The mechanism involves immunosuppressive mechanism may decrease tolerance to allergen immunotherapy. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Ustekinumab Aekn Class
- Interleukin-12 Antagonist
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Immunosuppressive mechanism may decrease tolerance to allergen immunotherapy
What To Tell Your Doctor or Pharmacist
If you are taking Allergen Immunotherapy and your doctor is considering prescribing Ustekinumab Aekn (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider